Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Remember??? Does this become our new spearhead while attorneys hash it out in court???

The U.S. Food and Drug Administration has granted orphan drug designation to RLF-100 (aviptadil), Relief Therapeutics’ investigational inhaled therapy for sarcoidosis.

Such status is given to treatment candidates with the potential to be safe and effective in rare diseases — defined in the U.S. as those affecting fewer than 200,000 people — that have no approved treatments, or in cases in which the potential therapy shows significant benefit over existing treatments.

https://sarcoidosisnews.com/2021/08/13/inhaled-therapy-rlf-100-sarcoidosis-earns-fda-orphan-drug-status/

As part of a new agreement with AdVita Lifescience, Relief Therapeutics will acquire the intellectual rights for the specifications and potential applications of an inhaled formulation of RLF-100 (aviptadil).

Relief has been collaborating with NeuroRx to advance the development of RLF-100 to treat patients with severe COVID-19 respiratory complications and other lung disorders, including pulmonary sarcoidosis.

https://sarcoidosisnews.com/2021/01/28/deal-gives-relief-therapeutics-intellectual-rights-potential-sarcoidosis-therapy-rlf-100/